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Abstract
Background—Consumer involvement in
clinical guidelines has long been advo-
cated although there are few empirical
accounts of attempts to do so. It is
therefore not surprising that there is a
lack of clarity about how and when to
involve consumers and what to expect
from them within the process of guideline
development.
Methods—The North of England evidence
based guideline development programme
has used four diVerent methods of con-
sumer involvement.
Results—When individual patients were
included in a guideline development group
they contributed infrequently and had
problems with the use of technical lan-
guage. Although they contributed most in
discussions of patient education, their
contributions were not subsequently acted
on. In a “one oV” meeting with a group of
patients there were again reported prob-
lems with medical terminology and the
group were most interested in sections on
patient education and self management.
However, their understanding of the use of
scientific evidence in order to contribute to
a more cost eVective health care remained
unclear. In a workshop it was possible to
explain the technical elements of guideline
development to patients who could then
engage with such a process and make
relevant suggestions as a consequence.
However, this was relatively resource in-
tensive. A patient advocate within a guide-
line development group felt confidence to
speak, was used to having discussions with
health professionals, and was familiar with
the medical terminology.
Conclusions—Consumers should be in-
volved in all stages of guideline develop-
ment. While this is possible, it is not
straightforward. There is no one right way
to accomplish this and there is a clear
need for further work on how best to
achieve it.
(Quality in Health Care 2001;10:10–16)
Keywords: patient involvement; patient education;
guideline development groups
Over the last decade clinical practice guidelines
have become an increasingly familiar part of
clinical care. Defined as “systematically devel-
oped statements to assist both practitioner and
patient decisions in specific circumstances”,1
they are viewed as useful tools for making care
more consistent and eYcient and for closing
the gap between what clinicians do and what
scientific evidence supports.2 The broad inter-
est in clinical guidelines is international3 4 and
has its origin in issues that most healthcare sys-
tems face: rising healthcare costs; variations in
service delivery with the presumption that at
least some of this variation stems from
inappropriate care; and the intrinsic desire of
healthcare professionals to oVer, and patients
to receive, the best care possible. Within the
UK there is ongoing interest in the develop-
ment of guidelines5 and a fast developing
Key messages
+ Consumers should be involved in all the
stages of guideline development to ensure
their views are heard.
+ Consumers (like all guideline develop-
ment group members) need support to
be able to understand the detail of the
science behind the issues they will hear
discussed and to be able to contribute to
discussion.
+ Having explored four diVerent methods
of involving consumers, none was ideal
and, even if optimised, each alone would
be likely to remain limited.
+ Given the greater degree of discussion
within a “one oV” group of patients than
by the sole patients within the guideline
groups, it seems reasonable to at least
oVer consumers within guideline groups
the option of being one of a pair.
+ It is feasible to support consumers to
understand the technical elements of
guideline development.
Implications of this work for quality
improvement
Consumers should be involved in all the
stages of guideline development to ensure
their views are heard, but experience on how
best to do this is limited. Future guideline
development groups should consider (and
report on) using more than a single method
of consumer involvement, such as involving
consumers both within guideline develop-
ment groups and other structures (focus
groups, consumer surveys) outside guide-
line development groups but feeding into
them.
.
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clinical eVectiveness agenda6 7 within which
guidelines figure prominently.
During the same 10 year period the methods
of developing guidelines have steadily im-
proved. Overall, methods have moved from
those based on unstructured (or even no)
review of the evidence, poorly constructed
development groups, and solely consensus
methods to methods that take explicit account
of systematically identified evidence, use multi-
disciplinary development groups and more
structured methods of gathering opinion.
However, within this overall improvement
there are some areas that remain less well
developed and described.
Consumer involvement in clinical guidelines
has long been advocated1 but there is a realistic
perception that attempts at involvement have
been driven by political correctness and
professional perspectives.8 It is striking that,
given the volume written about clinical guide-
lines, there are few empirical accounts of
attempts to involve consumers9 and suggested
frameworks for consumer involvement in
guidelines, while useful, appear to have come
out of no, or limited, practical experience.8 10 It
is therefore not surprising that there is a lack of
clarity about how and when to involve
consumers and what to expect from them
within the process of guideline development.11
There are good reasons for taking consumer
involvement seriously. Firstly, consumers will
have a diVerent knowledge, understanding,
and experience of the diagnosis and manage-
ment of the illness process from healthcare
professionals. These personal viewpoints and
experiences, at an individual or group level,
need to be considered when describing the
processes of clinical care. A better understand-
ing of the value of the consumer’s view is
therefore necessary in order to apply these to
the guideline development (and implementa-
tion) process in the most eYcient way.
Within the North of England evidence based
guideline development programme 10 evi-
dence based guidelines have been developed
and their methods of development have been
described.12–15 The period of development of
these guidelines spanned 6 years over which
time there was an evolving experience of
involving consumers. Four diVerent methods
of consumer involvement were used with some
being more successful than others. Three of
these were conducted directly within the pro-
cess of developing guidelines and fed into the
guideline recommendations. The other one
was conducted as an attempt to explore further
methods of involving consumers to inform
future guideline development. This paper
describes and discusses our experiences with
these diVerent methods as a series of case stud-
ies and, from this basis, suggests how these
methods could be developed.
Methods of involving consumers in
guideline development
The four methods, which were explored in
consecutive order, were:
+ incorporating individual patients in guide-
line development groups;
+ a “one oV” meeting with patients;
+ a series of workshops with patients;
+ incorporating a consumer advocate in
guideline development groups.
The first, second, and fourth were conducted
within the development of the guidelines. A
range of methods was used including direct
observation, individual interviews, and analysis
of audio transcripts.
INCORPORATING AN INDIVIDUAL PATIENT IN A
GUIDELINE DEVELOPMENT GROUP
For the development of guidelines for two
chronic conditions (asthma16 17 and angina18 19),
patients were invited to be members of
multidisciplinary guideline development
groups. Having failed to identify patients
through the Community Health Council, both
patients were identified through the secondary
care clinicians within the guideline groups.
They were invited as individuals who were felt
to have both the time and interest to partici-
pate. This was our first attempt to involve con-
sumers and, although the two patients were
integrated socially into the group, there was
neither explicit expectation from their involve-
ment nor any briefing or formal support for
them.
Community Health Councils
Community Health Councils were set up as
local independent bodies in 1974 to repre-
sent the interests of the public in the
National Health Service. They are statutory
bodies and have rights to information, to be
consulted, and to meet with Health Au-
thorities and National Health Service
Trusts.
In addition to the patient, each multidiscipli-
nary group involved primary care, secondary
care and public health doctors, primary care
nurses, and technical and administrative sup-
port staV. The process of guideline develop-
ment and the methodological issues raised have
been previously described.12 13 The eight meet-
ings of each group were audiotaped and
transcribed. In order to analyse the contribu-
tions of the patients, the transcripts were
content analysed. The summary findings of the
two groups are presented together (box 1).
On the whole, the contribution of these
patients towards the development of the
asthma and angina guidelines was small in
comparison with the contributions and com-
munications of the other group members. The
most vocal members of the groups were the
secondary care physicians who were presenting
summaries of the evidence to the other group
members. There was a range of rate of contri-
bution from the other (clinical) group mem-
bers. Although some spoke infrequently, their
contributions were usually acted upon. How-
ever, the female patient in the asthma group
hardly spoke, talking on average only once in a
meeting and used, at the most, three sentences
each time she spoke. The male patient in the
angina group spoke more, on average four
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times in a meeting, and used at the most 12
sentences. These diVerences might relate to sex
or to personality but could also be due to a dif-
ference in role perception. The patient in the
asthma group contributed to discussions solely
by giving illustrations of her own experiences.
However, the patient in the angina group, who
was also a member of a patient support group,
might have seen his role more as a mediator
between his patient group and the guideline
development group. Besides giving examples as
the asthma patient did, he also tried to link the
guideline process to the content of the patient’s
charter. Furthermore, he wanted to develop a
flow chart which, it became increasingly appar-
ent, the rest of the group did not want and did
not subsequently act upon.
Both patients indicated at several points that
they were not familiar with the medical
language spoken and asked for clarification of
terms and abbreviations. Furthermore, they
both contributed most within the discussions
on patient education. For the other sections on
drugs their main contribution was to give per-
sonal examples and this was mostly when spe-
cifically asked for their experiences or opinions
by the chairperson or other members of the
group. Otherwise, they were “participating
observers of technical language to which they
could hardly oVer any input”.13
“ONE OFF” MEETING WITH PATIENTS
The second method of involving patients in
guideline development was discussing an
advanced draft version of guidelines with a
group of patients at a single evening meeting.
The guidelines were an updated version of the
previously developed asthma guidelines.20 Pa-
tients were invited to attend via a local group of
the National Asthma Campaign. Those who
were interested in participating in the meeting
were sent a copy of the guidelines and were
asked to read these for a forum discussion with
the developers of the guidelines. At the meeting
the aims of the evening were stated as: (1) to
provide the background and rationale of the
guidelines; (2) to discuss the necessity of the
guidelines and the principle of evidence based
information; (3) to explain the meaning of the
strengths of the recommended treatments; and
(4) to discuss patient input for future guideline
development. The discussions were tape re-
corded, the text transcribed, and the content of
the transcripts analysed. The main points will
be summarised here (box 2).
The patients constructed the rationale of the
guidelines, in the sense of uniform diagnosis
and treatment, as positive because of their own
experiences of geographical and professional
variation in asthma care. Several patients
oVered the view that patients with asthma in
other parts of the UK received diVerent drugs
and advice from them. Furthermore, patients
were aware that, in some places, asthma nurses
were the main carers while, in other places,
doctors were in charge of caring for the
patients. Some thought that asthma nurses had
more knowledge and understanding of asthma
than GPs or consultants because “they have had
the training”.
Patients were often critical about the treat-
ment they had received for their asthma. Some
expressed a lack of confidence in clinicians, and
there were several examples of patients having
received conflicting information from diVerent
clinicians. They also felt they were not always
listened to, which led to examples of inappro-
priate clinical decisions. Furthermore, patients
complained about the lack of adequate infor-
mation: “people go in and out of the hospital with-
out being told what is happening”; “there is no one
to ask questions from”.
Patients also identified problems with the
use of medical terminology and jargon by clini-
cians, saying that this did not help in
understanding what was going on. As specific
examples, patients highlighted the word “ster-
oids” and the use of diVering terms for drug
delivery devices. They felt that when doctors
used the term “steroids” as the prescribed
drugs for asthma they seemed to forget the
negative connotations this might have for
patients for whom steroids are seen as forbid-
den drugs taken by top athletes. The other
aspect mentioned by patients was the naming
of drug delivery devices. Patients reported
thinking about the diVerent inhalers by their
colour. They described knowing exactly when
to use the blue inhaler, and when to get the
brown, orange, or green one. Furthermore,
they were more used to the brand names than
the generic names of the various drugs.
Healthcare professionals, on the other hand,
were felt to use the “chemical” names, as
reflected in the guidelines. This diVerence of
terminology seemed to lead to unnecessary
misunderstandings in the care process.
The sections of the guidelines that attracted
patients most were those on patient education
and self-management. However, personal
experience rather than the available evidence
influenced the views they expressed. The use of
peak flow meters and flow charts of readings
were examples of where they suggested pat-
terns of use that did not match with the content
of the guideline. However, they did identify
+ Patients contributed infrequently to the
discussions
+ Patients had problems with the use of
technical language
+ They contributed most in discussions of
patient education
+ Their contributions were not subse-
quently acted upon
Box 1 Incorporating an individual patient in a
guideline development group
+ Patients reported problems with medical
terminology and jargon
+ They were most interested in sections on
patient education and self-management
+ Their understanding of the use of scien-
tific evidence in order to contribute to a
more cost eVective health care remained
unclear
Box 2 “One oV”meeting with patients
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that they would like to have received infor-
mation on asthma in layman’s terms and in a
more simplified form. Interestingly, some
patients had brought information leaflets with
them to the meeting and pointed out the con-
tradictions between them. However, most of
these leaflets were written by pharmaceutical
companies promoting their own drugs. EVorts
to explain to the patients the role of these com-
panies in health care were not very successful.
Overall, the patients were interested in the
content of the meeting and their response to
the idea of guidelines was positive: “everything’s
got its own rules—you need rules to play hockey—
these are asthma rules”. Patients did show an
understanding of the applicability of the guide-
lines for more uniform diagnosis and treat-
ment; however, the underlying idea of the use
of scientific evidence to contribute to a more
cost eVective health care remained unclear.
WORKSHOPS WITH PATIENTS
The third method was the development of a
series of workshops to explore the potential to
increase patients’ understanding of the meaning
of scientific evidence, their ideas of cost
eVectiveness, and their views on patient infor-
mation. This method was explored outside the
guideline development process as an exercise to
see how much of the technical content of the
guideline could be explained to consumers. The
guideline was the same as that used in the single
meeting with patients and the patients were
again recruited through the local branch of the
National Asthma Campaign. Four workshops
were run by a psychologist member of the
research team (AvW) with an average attend-
ance of 10 patients. In the first two a role play
was carried out. In the last two sessions patient
information was explored in more detail and
suggestions for a patient version of the asthma
guidelines were discussed.
The scenario for the first role play was the
organisation of a party. Each patient received a
budget of £50 to do the shopping for a party at
home with 10 guests. They were asked to write
their shopping list and to prioritise the goods
they wished to buy. Each patient then told the
others in the group what they had bought and
the reasons for their choices.
The first observation was that nobody had
exactly the same shopping list. Some priori-
tised drinks, others food. The reasoning behind
their choices diVered as well. For example, for
the wine, four reasons for their choices were
mentioned: alcohol percentage of the wine,
price per bottle, habit (choosing the wine one
always drinks), and chance (choosing the wine
which happens to be on oVer). Finally, there
was a diVerence in quality and quantity. Some
patients ended up with only half as many gro-
ceries as others on the rationale of “the more
expensive, the better the quality”. This led to a
debate on quality and quantity, and how to
measure quality. The group was then asked to
set up a study to measure diVerences in quality
of bottles of wine costing £10 and £2.50. They
would ask people to drink both wines without
telling them which was which. They would
then question them about their preferences in
taste, colour, and price. Thus, the group
designed a simple trial. Following these role
plays, both randomised trials with asthma
drugs and the principle of evidence based rec-
ommendations were subsequently explained to
the patients with no diYculty.
In the second workshop the group was asked
to assume the role of the person responsible for
purchasing at their local district health author-
ity.With a budget of £500 they had to purchase
inhalers for their asthma patients. Four diVer-
ent companies oVered inhalers to them, each
claiming their own as the most eVective. The
inhalers diVered in cost (£1, £5, £15, and
£30), form (aerosol, powder), consequences
(taste, side eVects), and delivery device (colour,
size, design, mechanism). All four inhalers
came with an information leaflet claiming the
excellence of their product. The group showed
an increased awareness of reasons other than
cost in their choices, such as the demand for
inhalers, patient characteristics, and patient
preferences. None of the group members was
inclined to just buy the cheapest or the most
expensive (thus not following the principle “the
more expensive, the better”). Overall, the
group thought they could not make a responsi-
ble choice before independent (from the phar-
maceutical industry) studies had shown which
inhalers were better for which group of patients
(children, older people, people with or without
other ailments).
In the last two workshops information
leaflets and brochures on asthma were studied
in more detail. At the end of the third workshop
agreement was reached that a patient version of
the evidence based guidelines would be the
most reliable and up to date information for
patients. In the last workshop the development
of an evidence based guideline for asthma
patients was explored and several ideas were
suggested by the group. These included trans-
lating medical jargon into laymen’s terms, the
layout of the document (for example, use of
colour, pictures and a bigger font), suggestions
on the contents (for example, use of “strong
evidence” and “weak evidence” instead of the
letters A, B, C, and D), inclusion of a peak flow
booklet, use of colours and brand names by
inhalers and drugs, and explanation of the use
of steroids.
This method suggested that it is possible to
explain the technical elements of guideline
development to patients and that they can
engage with such a process and make relevant
suggestions as a consequence. However, the
process was relatively resource intensive (box 3).
INCORPORATING A PATIENT ADVOCATE IN A
GUIDELINE DEVELOPMENT GROUP
The final method used was the involvement of
a consumer advocate as a member of the group
developing a guideline on the secondary
preventive treatment of patients who have sur-
vived a myocardial infarction. The consumer
advocate was the head of a national cardiac
patient group and was recruited directly after
her involvement in the development of the
national service framework on coronary heart
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disease. A single telephone interview was con-
ducted covering the experiences and satisfac-
tion of the patient advocate herself and her
involvement in the development group.
She saw her role as liaising between (her)
patient group and the guideline group. Because
of her experiences working for the cardiac
patient association, she reported not feeling
overpowered by the other (healthcare profes-
sional) group members. She felt she had
enough confidence to speak up,mainly because
of her perceived equivalence of her participa-
tory role in the guideline group with the tasks
of her job. She had previous similar experi-
ences, was used to having discussions with
health professionals, was familiar with the
medical terminology and, if there was anything
she did not understand, she had access to sev-
eral sources to resolve this.
She felt the group worked well and that her
input and output were well balanced. She felt
that she got across to the other group members
the points she wanted to share. In addition, she
felt that she had learned a lot from the others in
the group.
Based on her experiences, she felt that the
ideal consumer representative within a guide-
line group should have a number of character-
istics. She suggested that they should not
themselves be a patient, should have a broad
knowledge of the physical condition and
patients’ experiences of coping with the illness,
should have involvement in patients’ feelings,
problems and situations, have an understand-
ing of patients’ needs, and training in counsel-
ling or communication skills. She also felt that
having personal experience with a patient was
an advantage (box 4).
Discussion
Four diVerent methods of patient involvement
in evidence based clinical guidelines have been
described, three of which were used in the
process of developing guidelines and one was
conducted to explore the potential of the
method for future use. According to William-
son21 three types of patient representatives
within working committees can be dis-
tinguished, depending on the contributions
and skills each can be expected to bring: (1)
fellow patients, who would mainly present their
own views; (2) member of a patient group, who
would present the group’s views; and (3)
patient advocates, who would present knowl-
edge of patient views. In this paper we have
described our experiences with all three types.
When individual patients were incorporated
into the guideline development groups their
contribution was small. According to group
dynamics theory,22 this could have been antici-
pated since one of the hypotheses is that “the
high status person both initiates and receives
more communication than the low status
person (p 286)”. It now seems self-evident that
patient involvement in a guideline group will
not work if the patient does not receive enough
information on the aims of, and their role in,
the group, is not briefed properly, and does not
feel comfortable in the group. Were this
method to be attempted again, as it surely will,
it would be important to address these issues.
Given the greater degree of discussion within
the “one oV” group of patients than by the sole
patients within the guideline groups, it seems
reasonable to at least oVer consumers within
guideline groups the option of being one of a
pair. This would not only provide more
tangible support, but also lessen the risk of only
hearing from a “lone” or “token” consumer.
The involvement of patients through the sin-
gle meeting and the workshops produced more
interaction and discussion. In the “one oV”
meeting patients were able to raise issues of
concern from their reading of the guideline and
to identify a number of areas where the guide-
line could be altered to make it more accessible
to non-clinicians. One of the main stumbling
blocks with this method was that it was not
possible to discuss meaningfully any of the
“scientific” content of the guideline and there-
fore patients could only talk from the basis of
their personal experience. However, from the
workshops it became apparent that patients
could understand the rationale of both scien-
tific evidence and cost eVectiveness in health
care when allowed to work through day to day
examples. However, to achieve this was rela-
tively resource intensive, taking four evening
meetings. Such resources may well be beyond
the scope of individual guideline development
groups but could be resourced by broader
guideline development programmes.
Our experiences with a patient advocate
showed this to be a feasible method of getting
consumer involvement. Personal involvement
with an illness is diVerent for a patient than for
a patient advocate. While discussing patients’
matters, health professionals will objectify and
generalise patients’ experiences. They will not
do this to deny the personal experience of the
patient, but to understand the commonality of
the problem.While this could be distressing for
the patients themselves, it should not be for the
patient advocate. Additionally, the presence of
a patient might inhibit the health professionals
+ It was possible to explain the technical
elements of guideline development to
patients
+ Patients could engage with such a process
and make relevant suggestions as a
consequence
+ The process was relatively resource inten-
sive
Box 3 Workshops with patients
+ The advocate had previous similar expe-
riences
+ She felt confidence to speak within the
group
+ She was used to having discussions with
health professionals
+ She was familiar with the medical termi-
nology
Box 4 Incorporating a patient advocate in a guide-
line development group
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in their open communications, which might be
less with a patient advocate being present. A
patient advocate, rather than a patient or mem-
ber of a patient support group, also goes some
way towards addressing the issue of diVerences
in status within multidisciplinary working
groups.
Having involved consumers within the
guideline development process, their contribu-
tions did not necessarily alter the content of the
guidelines. There are a number of possible
reasons for this. Firstly, the scope of the guide-
lines had been defined in fairly narrow medical
terms and at a stage when consumers were not
involved. Secondly, the process of guideline
development—with its focus on validity and
underlying evidence—deals less comfortably
with “non-evidence based” views and prefer-
ences. The Institute of Medicine1 suggested
that consumer views should influence recom-
mendations where there is no, or equivocal,
evidence. This is borne out by our experiences
in that patients were content with being guided
by evidence. In areas where there was no
evidence (such as how patients should be
treated interpersonally), all members of guide-
line groups supported general statements
about ensuring good clinician/patient commu-
nication.
These experiences highlight the issues of
how consumers should be involved in all the
stages of guideline development and what is
expected of them. Although each of the four
methods had advantages (and disadvantages),
none was ideal and, even if optimised, each
alone would be likely to remain limited.
Consumers need to sit as members of guideline
groups to ensure their views are heard. To
avoid hearing only a single view (where it is
likely there is a range), broader views can be
gathered from outside the groups. This could
be addressed by using more than a single
method of consumer involvement, an approach
that would fit with the highest of Bastian’s
“levels of involvement”.8 This would mean
involving consumers both within guideline
development groups and in other structures
(focus groups, consumer surveys) outside
guideline development groups but feeding into
them. Guideline development groups are now
starting to use such multiple methods. The
guideline development group for the stroke
guideline produced by the Royal College of
Physicians contained three patient organisation
representatives but also used focus groups to
explore patient and carer views.23
It is less clear how much support needs to be
provided to help consumers (or other group
members) to understand the detail of the
science behind the issues they will hear
discussed. To a greater or lesser extent, most
members of a guideline development group
will have limitations in their ability to under-
stand the detail of systematic review or health
economics, and the guideline development
process allows that these specialised skills will
be provided by specialists within the groups.
Appropriate support and training therefore
needs to be supplied to all members of
guideline development groups to allow them to
fulfil their role. It is reasonable to suppose that
some issues (hierarchies within groups, medi-
cal terminology) will be particularly height-
ened for consumers. Having achieved this, in
the absence of any specific shared role for
group members (such as sharing the reviewing
task), the role of a consumer then becomes the
same as that of any other group member—to
comment on the process of care and the issues
around this in the light of the available summa-
rised evidence. From the content of the
meeting and the workshops it is likely that this
will produce comment on the content and also
on the wording of recommendations and the
presentation of the guideline, both in general
and particularly if a specific patient version is to
be produced.
The National Institute for Clinical Excel-
lence is actively promoting consumer involve-
ment within guidelines developed within its
programme (M Kelson, personal communica-
tion). There is a growing body of guidance on
supporting user representatives to promote
more eVective involvement in other areas of
NHS activity.24 25 This will inform the methods
of involving consumers within guideline devel-
opment. Our experiences to date and that of
others24 suggests that it is possible to get mean-
ingful consumer involvement into guideline
development but that this is not straightfor-
ward. There is no one right way to accomplish
this and there is a clear need for further work
on how best to achieve it.
We are grateful to all of the consumers who have been involved
in the guideline development processes described; the National
Asthma Campaign for their support in setting up and running
the “one oV” meeting and the series of workshops; the Depart-
ment of Health for England and Wales for funding the guideline
development; and Nikki Rousseau for her help in running the
“one oV” meeting.
1 Field MJ, Lohr KN, eds. Guidelines for clinical practice: from
development to use. Washington DC: National Academy
Press, 1992.
2 Woolf SH, Grol R, Hutchinson A, et al. Clinical guidelines:
the potential benefits, limitations and harms of clinical
guidelines. BMJ 1999;318:527–30.
3 Grol R, Eccles M,Maisonneuve H, et al. Developing clinical
practice guidelines: the European experience. Dis Manage
Health Outcomes 1998;4:255–66.
4 Woolf S, Grol R, Hutchinson A, et al. An international over-
view. In: Eccles M, Grimshaw J, eds.Clinical guidelines: from
conception to use. Oxford: RadcliVe Medical Press, 2000:
31–48.
5 NHS Executive. Clinical guidelines: using clinical guidelines to
improve patient care within the NHS. London:HMSO, 1996.
6 Department of Health. The new NHS: modern, dependable.
London: Department of Health, 1997.
7 NHS Executive. A first class service: quality in the new NHS.
London: HMSO, 1998.
National Institute for Clinical
Excellence (NICE)
The National Institute for Clinical Excel-
lence (NICE) was set up as a Special Health
Authority for England and Wales on 1 April
1999. It is part of the National Health Serv-
ice and its role is to provide patients, health
professionals, and the public with authorita-
tive, robust and reliable guidance on current
“best practice”. Guidance covers both
individual health technologies (including
medicines, medical devices, diagnostic
techniques, and procedures) and the clinical
management of specific conditions.
Involvement of consumers in the development of evidence based clinical guidelines 15
www.qualityhealthcare.com
8 Bastian H. Raising the standard: practice guidelines and
consumer participation. Int J Quality Health Care 1996;8:
485–90.
9 Carver AD, Entwistle V. Patient involvement in SIGN
guideline development groups. Edinburgh: Scottish Associ-
ation of Health Councils, 1999.
10 DuV L, Kelson M, Marriott S, et al. Clinical guidelines:
involving patients and users of services. J Clin EVect 1996;
1:104–12.
11 Van Wersch A, Eccles M. Patient involvement in evidence-
based health in relation to clinical guidelines. In: Gabbay
M, ed. The evidence-based primary care handbook. London:
Royal Society of Medicine, 1999: 91–103.
12 Eccles MP, Clapp Z, Grimshaw JM, et al. North of England
evidence based guidelines development project: methods of
guideline development. BMJ 1996;312:760–1.
13 Eccles MP, Clapp Z, Grimshaw J, et al. Developing valid
guidelines: methodological and procedural issues from the
North of England evidence based guideline development
project. Quality in Health Care 1996;5:44–50.
14 Eccles M, Freemantle N, Mason J. North of England
evidence based guideline development project: methods of
developing guidelines for eYcient drug use in primary care.
BMJ 1998;316:1232–5.
15 Eccles M, Mason J, Freemantle N. Developing valid cost
eVectiveness guidelines: a methodological report from the
North of England evidence based guideline development
project. Quality in Health Care 2000;9:127–32.
16 North of England Evidence Based Guideline Development
Project. Evidence based clinical practice guideline: the primary
care management of asthma in adults. Report 75. Centre for
Health Services Research, Newcastle upon Tyne, 1996.
17 North of England Asthma Guideline Development Group.
North of England evidence based guidelines development
project: summary version of evidence based guideline for
the primary care management of asthma in adults. BMJ
1996;312:762–6.
18 North of England Evidence Based Guideline Development
Project. Evidence based clinical practice guideline: the primary
care management of stable angina. Report 74. Centre for
Health Services Research, Newcastle upon Tyne, 1996.
19 North of England Stable Angina Guidelines Development
Group. Evidence based guideline for the primary care
management of stable angina: summary version. BMJ
1996;312:827–32.
20 North of England Evidence Based Guideline Development
Project. The primary care management of asthma in adults.
Report 97. Centre for Health Services Research, Newcastle
upon Tyne, 1999.
21 Williamson C. The rise of doctor-patient working groups.
BMJ 1998;317:1374–7.
22 Shaw ME. Group dynamics. The psychology of small group
behaviour. New Delhi: Tata McGraw-Hill Publishing,
1977.
23 The Intercollegiate Working Party for Stroke.National clini-
cal guidelines for stroke. London: Royal College of Physi-
cians, 2000.
24 Kelson M.User involvement: a guide to developing eVective user
involvement strategies in the NHS. London: College of
Health, 1997.
25 Consumers in NHS Research Support Unit. Involving
consumers in research and development in the NHS: briefing
notes for researchers. Winchester: Help for Health Trust,
2000.
Cambridge International Health Leadership Programme
TRANSFORMING HEALTH: CREATING VALUE THROUGH CHANGING SYSTEMS
An intensive 8 day international seminar for health sector leaders
18–25 April 2001
Cambridge, UK
The Cambridge International Health Leadership Programme has been established to provide an annual forum in
which senior health sector leaders from around the world address the issues of health sector reform in the face of rapid
change and development. The seminar provides access to essential information and unparalleled management and
policy expertise. In consultation with leading international figures in the field, participants in this, the fifth seminar in
the series, will be able to identify ways to improve the performance of their country’s health sector for the 21st cen-
tury.
Through a combination of lectures, workshops, case analyses, and discussion groups the Programme will strengthen
and enrich the ability of participants to manage complexities and improve performance. Group work on selected top-
ics is integrated into the programme, constructed around participants’ own issues, giving delegates the opportunity to
learn from each other as well as with the faculty. They will learn the latest approaches to quality improvement and will
have the opportunity to develop their own plans and approach to managing and leading change.
Participation in the seminar will link delegates into an influential network involving both their peers, faculty, and the
agencies supporting and driving health sector reform.
The seminar is organised on behalf of the Judge Institute of Management Studies by the University of Cambridge
Programme for Industry.
Location
Sessions will be held at the Judge Institute of Management Studies in its stunning new building in the centre of Cam-
bridge. The Judge Institute is the University of Cambridge’s business school.
Programme Fee: £4900 (no VAT)
The fee includes all documentation, seminar notes, full accommodation (nights of Wednesday 18 April to Tuesday 24
April 2001), meals and other refreshments throughout the Seminar. The fee does not include travel expenses.
A limited number of bursaries are available for the event.
Nomination enquiries/further information
Please contact:
Francesca Barraud, Programme Manager, University of Cambridge Programme for Industry, 1 Trumpington Street,
Cambridge CB2 1QA, UK
Tel: +44 (0)1223 342100. Fax: +44 (0)1223 301122
email: francesca.barraud@cpi.cam.ac.uk
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www.qualityhealthcare.com
